Atea Pharmaceuticals Overview
Valuation check: AVIR's P/E ratio is -2.49, below the Healthcare sector average of 27.28.
Get informed when a big investor buys or sells
+ Follow-2.49
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Atea Pharmaceuticals (AVIR) currently reports a P/E ratio of -2.49. That is below the Healthcare sector average of 27.28. Use the charts on this page to explore Atea Pharmaceuticals's P/E ratio history and peer comparisons.
Atea Pharmaceuticals's P/E ratio of -2.49 is lower than the Healthcare sector average of 27.28. That is roughly 109.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Atea Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At -2.49, AVIR can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -2.49, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.28. From there, open related valuation or income-statement pages for Atea Pharmaceuticals, and consider following AVIR for alerts when major investors trade the stock.
Atea Pharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows -2.49 versus a sector average near 27.28. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AVIR with unrelated industries.
